Cellectar Biosciences, Inc. (CLRB) News
Filter CLRB News Items
CLRB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLRB News Highlights
- For CLRB, its 30 day story count is now at 3.
- Over the past 14 days, the trend for CLRB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and DRUG are the most mentioned tickers in articles about CLRB.
Latest CLRB News From Around the Web
Below are the latest news stories about CELLECTAR BIOSCIENCES INC that investors may wish to consider to help them evaluate CLRB as an investment opportunity.
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research FoundationExclusive License Agreement to Develop and Commercialize Pediatric Cancer TreatmentsFLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research condu |
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC PlatformExpanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer PayloadsFLORHAM PARK, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that is has received Notice of Allowance for the patent titled, “Phospholipid-flavagline conjug |
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit EuropePresentation to Discuss Advancing Universal Targeted RadiotherapiesFLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar’s chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being he |
Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call TranscriptCellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead. Monique Kosse: Thank you, operator, […] |
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that top-line data from the pivotal trial in Waldenstrom’s macroglobulinemia ( |
Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community SettingStrategic collaboration to advance patient care and further define the U.S. treatment landscape First of several planned community-based cancer care network collaborations for Cellectar to facilitate future patient access and clinical success with iopofosine I 131 FLORHAM PARK, N.J, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the trea |
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023FLORHAM PARK, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Thursday, November 2, 2023. Management will also host a conference call with investors to discuss financial results and provide an |
Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's MacroglobulinemiaWilliam Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aadity |
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent GrantsFLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio. Cellectar has secured four patents across the key global regions Europe, Australia and Canada, covering the company’s proprietary Phospholipid Drug Conjug |